ES2113870T3 - Utilizacion de n,n'-bis 3-(etilamino)propil-1,7-heptanodiamina y un agente citotoxico. - Google Patents

Utilizacion de n,n'-bis 3-(etilamino)propil-1,7-heptanodiamina y un agente citotoxico.

Info

Publication number
ES2113870T3
ES2113870T3 ES91121354T ES91121354T ES2113870T3 ES 2113870 T3 ES2113870 T3 ES 2113870T3 ES 91121354 T ES91121354 T ES 91121354T ES 91121354 T ES91121354 T ES 91121354T ES 2113870 T3 ES2113870 T3 ES 2113870T3
Authority
ES
Spain
Prior art keywords
antineoplastic
bis
cytotoxic agent
heptanodiamine
propil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91121354T
Other languages
English (en)
Inventor
Nellikunja J Prakash
Terry L Bowlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2113870T3 publication Critical patent/ES2113870T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ESTA INVENCION SE REFIERE A LA UTILIZACION DE N, N''-BIS[3-(ETILMINO) PROPIL]-1,7-HEPTANEDIAMINE Y UN AGENTE CITOTOXICO SELECCIONADO DEL GRUPO QUE CONSISTE DE UN ALCALOIDE ANTINEOPLASTICO, UN ANTIBIOTICO ANTINEOPLASTICO, UN ANTIMETABOLITO ANTINEOPLASTICO Y UN COMPLEJO DE COORDINACION ANTINEOPLASTICO PARA LA PREPARACION DE UNA COMPOSICION FARMACEUTICA UTIL PARA EL TRATAMIENTO DE UN PACIENTE QUE SUFRE DE UN ESTADO NEOPLASTICO.
ES91121354T 1990-12-13 1991-12-12 Utilizacion de n,n'-bis 3-(etilamino)propil-1,7-heptanodiamina y un agente citotoxico. Expired - Lifetime ES2113870T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62681490A 1990-12-13 1990-12-13

Publications (1)

Publication Number Publication Date
ES2113870T3 true ES2113870T3 (es) 1998-05-16

Family

ID=24511975

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91121354T Expired - Lifetime ES2113870T3 (es) 1990-12-13 1991-12-12 Utilizacion de n,n'-bis 3-(etilamino)propil-1,7-heptanodiamina y un agente citotoxico.

Country Status (11)

Country Link
EP (1) EP0490380B1 (es)
JP (1) JPH04275233A (es)
KR (1) KR100195423B1 (es)
AT (1) ATE163264T1 (es)
AU (1) AU648846B2 (es)
DE (1) DE69128926T2 (es)
DK (1) DK0490380T3 (es)
ES (1) ES2113870T3 (es)
GR (1) GR3026432T3 (es)
IE (1) IE914331A1 (es)
ZA (1) ZA919695B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910485A (en) * 1996-01-31 1999-06-08 Japan Science And Technology Corporation Antitumor agents comprising as the principal compounds containing silicon and nitrogen
US6274561B1 (en) 1997-01-29 2001-08-14 Japan Science & Technology Corp. Antitumor agents comprising as the principal compounds containing silicon and nitrogen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ223340A (en) * 1987-02-03 1991-03-26 Merrell Dow Pharma Polyamine derivatives and pharmaceutical compositions
EP0378146B1 (en) * 1989-01-10 1995-03-29 Merrell Pharmaceuticals Inc. Polyamine derivatives as antineoplastic agents
ZA903804B (en) * 1989-05-23 1991-03-27 Merrell Dow Pharma A method of potentiating cell-mediated immunity utilizing polyamine derivatives

Also Published As

Publication number Publication date
AU648846B2 (en) 1994-05-05
ZA919695B (en) 1992-09-30
ATE163264T1 (de) 1998-03-15
KR920011481A (ko) 1992-07-24
DE69128926D1 (de) 1998-03-26
JPH04275233A (ja) 1992-09-30
EP0490380A2 (en) 1992-06-17
DE69128926T2 (de) 1998-06-04
EP0490380B1 (en) 1998-02-18
EP0490380A3 (en) 1993-03-10
IE914331A1 (en) 1992-06-17
AU8890791A (en) 1992-06-18
DK0490380T3 (da) 1998-09-23
GR3026432T3 (en) 1998-06-30
KR100195423B1 (ko) 1999-06-15

Similar Documents

Publication Publication Date Title
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
DE68919236D1 (de) Textilbehandlungszubereitung und deren Herstellung.
IL96995A0 (en) Pharmaceutical compositions containing pimobendan and their preparation
PH30083A (en) Treatment of lower urinary tract disorders
ATE114974T1 (de) Abgabe von cytotoxischen mitteln.
DK0458589T3 (da) Behandling af okulær hypertension med en okulær synergistisk kombination
ES2113870T3 (es) Utilizacion de n,n'-bis 3-(etilamino)propil-1,7-heptanodiamina y un agente citotoxico.
IL90499A0 (en) Therapeutic uses of 2',5'-oligoadenylates
FR2522968B1 (fr) Medicament cytotoxique forme de l'association d'a u moins une immunotoxine et de la chloroquine
GR3022706T3 (en) Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases
FR2699920B1 (fr) Dérivés d'imidazo [2,1-b] benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique.
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
FR2700546B1 (fr) Dérivés d'imidazo[2,1-b]benzoxazole-3-acétamide, leur préparation et leur application en thérapeutique.
FR2717814B1 (fr) Dérivés de 1,2,4-triazolo(4,3-a)pyrazine-4-one, leur préparation et les médicaments les contenant.
ATE10095T1 (de) 10-substituierte 5-cyanmethylen-10,11-dihydrodibenzo-(a,d)-cycloheptene, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel.
FR2700337B1 (fr) Dérivés d'imidazopyridine-2-one, leur procédé de préparation et leur utilisation en thérapeutique.
Palani Professor Dr. N. Subbu Reddiar's contributions for the enrichment of Tamil
IT1242026B (it) Composizione farmaceutica contenente un complesso ferro-schizokinene per il trattamento dell'anemia ferropenica.
FR2700544B1 (fr) Dérivés de 9H-imidazo[1,2-a]benzimidazole-3-acétamide, leur préparation et leur application en thérapeutique.
FR2707987B1 (fr) Dérivés de 9H-imidazo[1,2-a]benzimidazole-3-acétamide, leur préparation et leur application en thérapeutique .
EP0311467A3 (en) Use of pyrroloû3,2,1-hi¨indole derivatives in the manufacture of a medicament for the treatment of diabetes
FR2715658B1 (fr) Dérivés de N-(3-aminopropyl)-N-phényl-5,6,7,8-tétrahydronaphtalène-2-carboxamide, leur préparation et leur application en thérapeutique.
IT8819879A0 (it) Composizioni farmaceutiche atte all'impiego nella terapia dell'ipotensione arteriosa.
FR2700547B1 (fr) Dérivés d'imidazo[2,1-b]benzosélénazole-3-acétamide, leur préparation et leur application en thérapeutique.
IT8820026A0 (it) Composizioni farmaceutiche adattivita' antineoplastica.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 490380

Country of ref document: ES